Description:
Recombinant Human Thrombopoietin produced in E.Coli is a single, non-glycosylated polypeptide chain containing 174 amino acids and having a molecular mass of 18608 Dalton which comprises the receptor binding domain of the Mpl-ligand protein.
Recombinant Human Thrombopoietin is purified by proprietary chromatographic techniques.
Source:
E. coli
Physical Appearance:
Sterile Filtered White lyophilized (freeze-dried) powder.
Formulation:
Lyophilized from a concentrated (1mg/ml) solution in water containing no additives.
Solubility:
It is recommended to reconstitute the lyophilized Recombinant TPO in sterile 18MΩ-cm H2O not less than 100µg/ml, which can then be further diluted to other aqueous solutions.
Stability:
Lyophilized Recombinant TPO although stable at room temperature for 3 weeks, should be stored desiccated below -18 C. Upon reconstitution Recombinant TPO should be stored at 4 C between 2-7 days and for future use below -18 C. For long term storage it is recommended to add a carrier protein (0.1% HSA or BSA).
Please avoid freeze-thaw cycles.
Purity:
Greater than 98.0% as determined by:
(a) Analysis by RP-HPLC.
(b) Anion-exchange FPLC.
(c) Analysis by reducing and non-reducing SDS-PAGE Silver Stained.
Amino Acid Sequence:
The sequence of the first five N-terminal amino acids was determined and was found to be Ser-Pro-Ala-Pr-Pro.
Dimers and Aggregates:
Less than 1% as determined by silver-stained SDS-PAGE gel analysis.
Biological Activity:
PLR’s Recombinant TPO is fully biologically active when compared to standard. The ED50 as determined by the dose-dependant stimulation of MO7e cells is less then 1 ng/ml, corresponding to a Specific Activity of 1 x 10 6 IU/mg.
Endotoxin:
Less than 0.1 ng/µg (IEU/µg) of TPO.
Protein content:
Protein quantitation was carried out by two independent methods:
1. UV spectroscopy at 280 nm.
2. Analysis by RP-HPLC, using a calibrated solution of TPO as a Reference Standard.
Usage:
PLR's products are furnished for LABORATORY RESEARCH USE ONLY.
